KR950000150A - 입사피론 의약 제제 - Google Patents
입사피론 의약 제제 Download PDFInfo
- Publication number
- KR950000150A KR950000150A KR1019940013308A KR19940013308A KR950000150A KR 950000150 A KR950000150 A KR 950000150A KR 1019940013308 A KR1019940013308 A KR 1019940013308A KR 19940013308 A KR19940013308 A KR 19940013308A KR 950000150 A KR950000150 A KR 950000150A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical formulation
- incident
- diffusion
- pyrone
- formulation according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
본 발명은 활성 화합물의 한정된 방출을 갖는 확산 제어 펠릿 또는 침식 정제로 이루어진 지속적인 작용, 고생체이용율 및 양호한 저장 안정성을 갖는 입사피론 의약 제제 및 그의 제조 방법 및 용도에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 실시예 6의 본 발명의 서방 제제와 실시예 1의 즉시 방출 입사피론 정제의 방출 시험 결과를 비교 도시한 그래프.
Claims (10)
- 80%/5시간 내지 80%/13시간의 평균 방출 속도 및 방출 초기 2시간 동안 35% 미만의 입사피론이 방출되는 초기 방출 속도를 갖는 입사피론 제약 제제.
- 제1항에 있어서, 확산 제어 펠릿 또는 정제 형태의 입사피론 제약 제제.
- 제2항에 있어서, 확산 제어 펠릿이 활성 화합물 및 결합제의 혼합물로 코팅시키고, 이어서, 확산층으로 코팅시킨 중심 펠릿으로 이루어진 것이 특징인 입사피론 제약 제제.
- 제2항 또는 제3항에 있어서, 확산층이 통상적인 확산 래커 및 통상적인 가소제로 이루어진 것이 특징인 확산 제어 펠릿 형태의 입사피론 제약 제제.
- 제2항 내지 제4항중 어느 한 항에 있어서, 히드록시프로필메틸셀룰로오스를 결합제로서 사용하고, Aquacoat를 확산 래커로서 사용하고, 트리아세틴을 가소제로 사용하는 것이 특징인 확산 제어 펠릿 형태의 입사피론 제약 제제.
- 활성 화합물을 필요에 따라 첨가제와 함께 물에 현탁시키거나 용해시키고, 결합제의 용액으로 농후화시키고, 이 현탁액을 중심 펠릿에 도포시키고, 이 코팅된 펠릿을 확산 래커와 가소제의 혼합물로 코팅시키는 것이 특징인 제2항 내지 제5항 기재의 확산 제어 펠릿형 입사피론 제약 제제의 제조 방법.
- 제2항에 있어서, 활성 화합물 및 통상적인 정제 제조용 보조제 이외에 수용성, 히드로겔 형성 중합체를 함유하는 정제 형태의 입사피론 제약 제제.
- 제7항에 있어서, 활성 화합물 이외에 150mPa·s 이상의 점도를 갖는 히드록시프로필셀룰로오스 50mg 이상을 함유하는 것이 특징인 정제 형태의 입사피론 제약 제제.
- 제1항 내지 제7항중 어느 한 항에 있어서, 추가로 생리학적으로 허용되는 산을 함유하는 것을 특징인 입사피론 제약 제제.
- 불안증 및 우울증 치료를 위한 제1항 내지 9항 기재의 입사피론 제제의 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4319760A DE4319760A1 (de) | 1993-06-15 | 1993-06-15 | Ipsapiron Arzneimittelzubereitung |
DEP4319760.4 | 1993-06-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR950000150A true KR950000150A (ko) | 1995-01-03 |
Family
ID=6490360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019940013308A KR950000150A (ko) | 1993-06-15 | 1994-06-14 | 입사피론 의약 제제 |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0629402A1 (ko) |
JP (1) | JPH06345649A (ko) |
KR (1) | KR950000150A (ko) |
CN (1) | CN1099263A (ko) |
AU (1) | AU6345794A (ko) |
CA (1) | CA2125620A1 (ko) |
CZ (1) | CZ146494A3 (ko) |
DE (1) | DE4319760A1 (ko) |
FI (1) | FI942803A (ko) |
HU (1) | HUT70759A (ko) |
IL (1) | IL109993A0 (ko) |
NO (1) | NO942228L (ko) |
NZ (1) | NZ260732A (ko) |
PL (1) | PL303822A1 (ko) |
SK (1) | SK72494A3 (ko) |
ZA (1) | ZA944187B (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
ES2211215T3 (es) * | 1998-12-24 | 2004-07-01 | Janssen Pharmaceutica N.V. | Composicion de galantamina de liberacion controlada. |
WO2004103338A1 (en) * | 2003-05-19 | 2004-12-02 | Bioprogress Plc | Adhesives and film modifying compositions |
JP2023508090A (ja) * | 2020-09-02 | 2023-02-28 | 北京華昊中天生物医薬股▲ふん▼有限公司 | ウチデロンの経口固形製剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE59000232D1 (de) * | 1989-02-11 | 1992-09-10 | Bayer Ag | Arzneimittel mit kontrollierter wirkstoffabgabe. |
DD297767A5 (de) * | 1990-03-06 | 1992-01-23 | Bayer Aktiengesellschaft,De | Arzneimittel mit kontrollierter wirkstoffabgabe |
JPH04360826A (ja) * | 1991-06-07 | 1992-12-14 | Bayer Yakuhin Kk | 放出制御製剤 |
-
1993
- 1993-06-15 DE DE4319760A patent/DE4319760A1/de not_active Withdrawn
-
1994
- 1994-05-31 AU AU63457/94A patent/AU6345794A/en not_active Abandoned
- 1994-06-03 EP EP94108571A patent/EP0629402A1/de not_active Withdrawn
- 1994-06-09 JP JP6150640A patent/JPH06345649A/ja active Pending
- 1994-06-10 CA CA002125620A patent/CA2125620A1/en not_active Abandoned
- 1994-06-13 IL IL10999394A patent/IL109993A0/xx unknown
- 1994-06-13 PL PL94303822A patent/PL303822A1/xx unknown
- 1994-06-13 NZ NZ260732A patent/NZ260732A/en unknown
- 1994-06-13 FI FI942803A patent/FI942803A/fi unknown
- 1994-06-14 HU HU9401771A patent/HUT70759A/hu unknown
- 1994-06-14 CZ CZ941464A patent/CZ146494A3/cs unknown
- 1994-06-14 SK SK724-94A patent/SK72494A3/sk unknown
- 1994-06-14 NO NO942228A patent/NO942228L/no unknown
- 1994-06-14 KR KR1019940013308A patent/KR950000150A/ko not_active Application Discontinuation
- 1994-06-14 ZA ZA944187A patent/ZA944187B/xx unknown
- 1994-06-15 CN CN94106657A patent/CN1099263A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
HUT70759A (en) | 1995-10-30 |
FI942803A (fi) | 1994-12-16 |
FI942803A0 (fi) | 1994-06-13 |
NZ260732A (en) | 1996-02-27 |
PL303822A1 (en) | 1995-01-09 |
DE4319760A1 (de) | 1994-12-22 |
AU6345794A (en) | 1994-12-22 |
CA2125620A1 (en) | 1994-12-16 |
IL109993A0 (en) | 1994-10-07 |
ZA944187B (en) | 1995-02-08 |
NO942228L (no) | 1994-12-16 |
SK72494A3 (en) | 1995-04-12 |
NO942228D0 (no) | 1994-06-14 |
EP0629402A1 (de) | 1994-12-21 |
CZ146494A3 (en) | 1995-01-18 |
CN1099263A (zh) | 1995-03-01 |
HU9401771D0 (en) | 1994-09-28 |
JPH06345649A (ja) | 1994-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8747898B2 (en) | Controlled release oral dosage form | |
EP0250267B1 (en) | Controlled absorption pharmaceutical composition | |
ES2606463T3 (es) | Combinación de formas de dosificación de levodopa/carbidopa de liberación inmediata y liberación controlada | |
JP2667214B2 (ja) | 徐放性製剤 | |
US6117453A (en) | Solid compositions containing polyethylene oxide and an active ingredient | |
US6589553B2 (en) | Controlled release oral dosage form | |
AU658209B2 (en) | Pharmaceutical combination formulation | |
AU757915B2 (en) | Controlled release bupropion formulation | |
JPH0643312B2 (ja) | 薬学的調合剤 | |
CA1319616C (en) | Long-acting diclofenac sodium preparation | |
CA2686094A1 (en) | Manufacturing method of a semiconductor element | |
PL191692B1 (pl) | Sposób wytwarzania doustnych, stałych produktów farmaceutycznych z regulowanym wydzielaniem substancji czynnej | |
HU227490B1 (en) | Sustained release pharmaceutical preparation containing carvedilol | |
US10213389B2 (en) | Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride | |
US4758437A (en) | Composition for long acting nicardipine preparation and process of producing the composition | |
MX2010011409A (es) | Forma oral solida con perfil de liberacion dual que contiene particulas multiples. | |
EP0211991A1 (en) | Substained release tablets and method for preparation thereof | |
US20030035840A1 (en) | Controlled release oral dosage form | |
KR950000150A (ko) | 입사피론 의약 제제 | |
DE60319983T2 (de) | Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan | |
CA2433915C (en) | Improved controlled release oral dosage form | |
Ayesha Farhana et al. | Sustained release of verapamil hydrochloride from sodium alginate microcapsules | |
JP2947841B2 (ja) | 徐放性固形製剤 | |
KR940008415B1 (ko) | 코팅 막과 그로부터 제조된 조성물 | |
JP2005510449A (ja) | 改良型制御放出経口剤形 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |